Upload
Featured Recent Articles Topics Login Upload

Search Results for 'tdf study'

tdf study published presentations and documents on DocSlides.

DTG + TAF/FTC vs DTG + TDF/FTC vs EFV/TDF/FTC
DTG + TAF/FTC vs DTG + TDF/FTC vs EFV/TDF/FTC
by iris
ADVANCE. . Design. Primary endpoint. Proportion ...
Raltegravir + Darunavir/r versus TDF-FTC + Darunavir/r RADAR Trial
Raltegravir + Darunavir/r versus TDF-FTC + Darunavir/r RADAR Trial
by keanu817
RADAR Trial. Raltegravir. + Darunavir/r versus TD...
Switch from TDF to TAF
Switch from TDF to TAF
by easyho
GS-US-292-0109 Study. GS-US-311-1089 Study. . De...
Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2)
Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2)
by zane419
Study 105. Atazanavir + [Cobicistat or Ritonavir] ...
Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112
Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112
by micah
Tenofovir. . Disoproxil. . Fumarate. to . Tenof...
Comparison of NNRTI vs NNRTI
Comparison of NNRTI vs NNRTI
by tatyana-admore
ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR...
The Bangkok Tenofovir Study
The Bangkok Tenofovir Study
by marina-yarberry
An HIV pre-exposure prophylaxis trial in Thailand...
Phase 2 of new ARVs
Phase 2 of new ARVs
by mitsue-stanley
Fostemsavir. , . prodrug. of . temsavir. . (. a...
Fixed-Dose Combination of
Fixed-Dose Combination of
by myesha-ticknor
Doravirine. /Lamivudine/TDF is Non-Inferior to . ...
ART as prevention: PEP &
ART as prevention: PEP &
by phoebe-click
PrEP. Dr. Laura Waters. HIV/GU Medicine. Brighto...
Tenofovir
Tenofovir
by alida-meadow
based . PrEP. technologies in women : . what do...
Switch
Switch
by lindy-dunigan
from. TDF to TAF. GS-US-292-0109 Study. GS-US-31...
Switch to DRV/r + RAL
Switch to DRV/r + RAL
by debby-jeon
SPARE . Study. SPARE Study: switch to DRV/r + RAL...
NRTI-sparing
NRTI-sparing
by liane-varnes
SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A40...
Switch to EVG/c/FTC/TDF
Switch to EVG/c/FTC/TDF
by liane-varnes
STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Desi...
Comparison of INSTI vs PI
Comparison of INSTI vs PI
by cheryl-pisano
FLAMINGO. GS-236-0103. ACTG A5257. WAVES . ARIA ....
Clinical Management Module
Clinical Management Module
by stefany-barnette
4. . (b) . Risks and Side Effects. Overview. Res...
ART Initiation: PrEP and
ART Initiation: PrEP and
by alida-meadow
Treatment-naïve Patients . Clinical Instructor, ...
Pre-exposure Prophylaxis for HIV Prevention
Pre-exposure Prophylaxis for HIV Prevention
by pamella-moone
Efficacy and the importance of adherence. Joanne ...
What’s Next – and When:
What’s Next – and When:
by sherrill-nordquist
An Update on Injectable . P. revention. Alex R Ri...
Comparison of NNRTI vs NNRTI
Comparison of NNRTI vs NNRTI
by lindy-dunigan
ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR...
CROI Update: Best of Boston
CROI Update: Best of Boston
by triclin
p. resented by. NCATEC. March . 18, . 2014. David ...
Phase 2 of new ARVs Fostemsavir
Phase 2 of new ARVs Fostemsavir
by sportyinds
, . prodrug. of . temsavir. . (. attachment inhi...
Brad Hare Nothing to Disclose
Brad Hare Nothing to Disclose
by beatrice
Kaiser Permanente San Francisco Medical Center. Sa...
NRTI-sparing SPARTAN PROGRESS
NRTI-sparing SPARTAN PROGRESS
by shepard237
RADAR. NEAT001/ANRS 14. 3 . A4001078. VEMAN. MODER...
Switch to ATV/
Switch to ATV/
by cheryl-pisano
r. + RAL. HARNESS Study. ATV/. r. 300/100 mg ....
Innovative Strategies for the Management
Innovative Strategies for the Management
by karlyn-bohler
of HIV Infection. Dual therapies without NRTIs. J...
A Demonstration Open Label
A Demonstration Open Label
by jane-oiler
Study to Assess the . Acceptability. , Safety. a...
ADOLESCENT PrEP STUDIES
ADOLESCENT PrEP STUDIES
by min-jolicoeur
. . Shorai. . Mukaka. , . MBchB. ...
Switch to DRV/r + 3TC DUAL Study
Switch to DRV/r + 3TC DUAL Study
by jireh
DRV/r 800/100 + 3TC 300 QD. N = 126. N = 123. DRV/...
Switch to PI/r + 3TC
Switch to PI/r + 3TC
by lois-ondreau
vs. PI/r . monotherapy. Study PIVOT. Study MOBID...
CROI 2015: HIV Prevention Updates
CROI 2015: HIV Prevention Updates
by pamella-moone
Ruanne V Barnabas, . MBChB. . Dphil. Global Heal...
Comparison of INSTI vs PI
Comparison of INSTI vs PI
by conchita-marotz
FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . De...
Comparison of INSTI vs PI
Comparison of INSTI vs PI
by conchita-marotz
FLAMINGO. GS-236-0103. ACTG A5257. WAVES. ARIA . ...
ID Week 2016: HIV Update
ID Week 2016: HIV Update
by min-jolicoeur
Robert Harrington, M.D.. ID Week 2016: HIV Update...
Comparison of INSTI vs INSTI
Comparison of INSTI vs INSTI
by pamella-moone
QDMRK. SPRING-2. ONCEMRK. ONCEMRK. Design. Object...
Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine
Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine
by luanne-stotts
Chief, Division of Infectious Diseases. Weill Med...
Characteristics and Oral
Characteristics and Oral
by lois-ondreau
PrEP. Adherence in the TDF2 Open-Label Extension...
Highlights for clinical
Highlights for clinical
by pasty-toler
. practice. HIV. International Congress of Drug ...
Modifying Therapy in the Treatment-experienced Patient:
Modifying Therapy in the Treatment-experienced Patient:
by yoshiko-marsland
When should it be done?. Professor of Medicine. U...